Bacteremias due to VRE resulted in significantly greater morbidity and higher rates of mortality than did VSE infections. Treatment of VRE infections Most enterococci including VRE are susceptible to nitrofurantoin , which may be used to treat UTIs. Most VRE faecalis remain susceptible to ampicillin, but exhibit high-level aminoglycoside resistance. This precludes the use of ampicillin-aminoglycoside combination therapy for a bactericidal effect, which is essential for the treatment of endocarditis and meningitis. Treatment of VRE faecium is very difficult because it is often highly resistant to ampicillin, and some strains are resistant to all currently available antimicrobial agents.
Aplastic anemia is extremely rare.
All of these agents are only bacteriostatic and therefore a marked reduction in the level of immunosuppressive therapy is necessary to help the patient overcome the infection. However, the value of trovafloxacin in the treatment of VRE in transplant patients remains to be confirmed by clinical trials. In addition, several questions remain to be answered. It has been shown to be effective against E. faecium but not against E. faecalis. It is also effective against Staphylococcus, Streptococcus, Neisseria, Hemophilus influenza, Moraxella, and anaerobic organisms.